Oxford BioDynamics PLC, a biotechnology company specializing in precision medicine tests, has announced that it will release its interim results for the half-year ended 31 March 2024 on Tuesday 18 June 2024. Following the release, the company's management team will conduct a live presentation to investors via the Yellowstone Advisory webinar platform. The online presentation is open to both existing and potential shareholders, with the opportunity to submit questions before and during the event.

The company's flagship products include the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. These tests are designed to advance personalized healthcare by providing predictive immune response profiles for immuno-oncology checkpoint inhibitor treatments and boosting the predictive accuracy of PSA tests for prostate cancer. Additionally, the company has launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test), and a microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.

Oxford BioDynamics has established numerous partnerships with major pharmaceutical companies and leading institutions, leveraging its proprietary 3D genomic biomarker platform, EpiSwitch®, to develop molecular diagnostic classifiers for various medical applications. The company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics, and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.

Headquartered in Oxford, UK, and listed on AIM of the London Stock Exchange, Oxford BioDynamics also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, as well as a reference laboratory in Penang, Malaysia. For more information, interested parties can visit the company's website or follow OBD on Twitter and LinkedIn.

The EpiSwitch® platform, which plays a crucial role in gene regulation by mapping the 3D configuration of the genome and identifying abnormal configurations, is at the core of the company's product portfolio. This platform is utilized to diagnose patients and develop precision medicine tests for various life-changing diseases.